LinkedIn Profile

Access Appili Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:appilitherapeutics 10172891 Nov 18th, 2019 12:00AM Appili Therapeutics 609 20.00 Open Biotechnology Nov 18th, 2019 03:41PM Nov 18th, 2019 03:41PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 16th, 2019 12:00AM Appili Therapeutics 609 21.00 Open Biotechnology Nov 16th, 2019 03:53PM Nov 16th, 2019 03:53PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 15th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 15th, 2019 12:35PM Nov 15th, 2019 12:35PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 14th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 14th, 2019 05:50PM Nov 14th, 2019 05:50PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 13th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 13th, 2019 01:02PM Nov 13th, 2019 01:02PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 12th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 12th, 2019 02:45PM Nov 12th, 2019 02:45PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 11th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 11th, 2019 02:43PM Nov 11th, 2019 02:43PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 10th, 2019 12:00AM Appili Therapeutics 608 21.00 Open Biotechnology Nov 10th, 2019 05:49PM Nov 10th, 2019 05:49PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 9th, 2019 12:00AM Appili Therapeutics 607 21.00 Open Biotechnology Nov 9th, 2019 05:16PM Nov 9th, 2019 05:16PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics
private:appilitherapeutics 10172891 Nov 8th, 2019 12:00AM Appili Therapeutics 606 21.00 Open Biotechnology Nov 8th, 2019 02:27PM Nov 8th, 2019 02:27PM Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company’s ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili’s medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili’s ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA’s 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501. Open Open Appili Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.